Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Section 6 of 6

References

165 sources

  1. Abida et al. (2019) (opens in a new tab)
  2. Agarwal et al. (2023) (opens in a new tab)
  3. Agarwal et al. (2025) (opens in a new tab)
  4. Akeega prescribing information (2025) (opens in a new tab)
  5. Alumkal and Ellis (2026) (opens in a new tab)
  6. American Cancer Society (2026) (opens in a new tab)
  7. American Cancer Society signs and symptoms (2026) (opens in a new tab)
  8. Annala et al. (2021) (opens in a new tab)
  9. Antonarakis et al. (2014) (opens in a new tab)
  10. Antonarakis et al. (2020) (opens in a new tab)
  11. Appukkuttan et al. (2021) (opens in a new tab)
  12. Attard et al. (2018) (opens in a new tab)
  13. AUA (2026) (opens in a new tab)
  14. Beltran et al. (2016) (opens in a new tab)
  15. Bosch et al. (2026) (opens in a new tab)
  16. California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026) (opens in a new tab)
  17. Caram et al. (2020) (opens in a new tab)
  18. Castro et al. (2025) (opens in a new tab)
  19. Castro et al. (2026) (opens in a new tab)
  20. Clarke et al. (2022) (opens in a new tab)
  21. ClinicalTrials.gov NCT03480646 (opens in a new tab)
  22. ClinicalTrials.gov NCT03480646 results (opens in a new tab)
  23. ClinicalTrials.gov NCT04179864 (opens in a new tab)
  24. ClinicalTrials.gov NCT04179864 results (opens in a new tab)
  25. ClinicalTrials.gov NCT05413421 (opens in a new tab)
  26. ClinicalTrials.gov NCT06551324 (opens in a new tab)
  27. ClinicalTrials.gov NCT07028853 (opens in a new tab)
  28. ClinicalTrials.gov NCT07723248 (opens in a new tab)
  29. CMS Enhancing Oncology Model (opens in a new tab)
  30. CMS Medicare Part B Payment Limit File (2026) (opens in a new tab)
  31. CMS negotiated prices fact sheet (2025) (opens in a new tab)
  32. CMS OPPS Addendum B (2026) (opens in a new tab)
  33. Corn et al. (2019) (opens in a new tab)
  34. Daemen et al. (2021) (opens in a new tab)
  35. Daemen et al. (2025) (opens in a new tab)
  36. de Bono et al. (2010) (opens in a new tab)
  37. de Bono et al. (2018) (opens in a new tab)
  38. de Bono et al. (2020) (opens in a new tab)
  39. de Feria Cardet et al. (2021) (opens in a new tab)
  40. de Wit et al. (2019) (opens in a new tab)
  41. EAU (2026) (opens in a new tab)
  42. eCQI Resource Center CMS645v9 (2026) (opens in a new tab)
  43. eCQI Resource Center CMS645v9 specification (2026) (opens in a new tab)
  44. Erleada prescribing information (2026) (opens in a new tab)
  45. FDA Tazverik safety alert (2026) (opens in a new tab)
  46. Fendler et al. (2023) (opens in a new tab)
  47. Fizazi et al. (2011) (opens in a new tab)
  48. Fizazi et al. (2020) (opens in a new tab)
  49. Fizazi et al. (2023a) (opens in a new tab)
  50. Fizazi et al. (2023b) (opens in a new tab)
  51. Fizazi et al. (2025) (opens in a new tab)
  52. Fizazi et al. (2026) (opens in a new tab)
  53. Flannery et al. (2026) (opens in a new tab)
  54. Freedland et al. (2023) (opens in a new tab)
  55. Freedland et al. (2024) (opens in a new tab)
  56. Friedman (2024) (opens in a new tab)
  57. Friedman et al. (2026) (opens in a new tab)
  58. Gandaglia et al. (2014) (opens in a new tab)
  59. George et al. (2026) (opens in a new tab)
  60. Gharzai et al. (2023) (opens in a new tab)
  61. Giri et al. (2025) (opens in a new tab)
  62. Gogebakan et al. (2026) (opens in a new tab)
  63. Hagiwara et al. (2013) (opens in a new tab)
  64. Halabi et al. (2016) (opens in a new tab)
  65. Hofman et al. (2021) (opens in a new tab)
  66. Hofman et al. (2024) (opens in a new tab)
  67. Hussain et al. (2020) (opens in a new tab)
  68. Jain et al. (2025) (opens in a new tab)
  69. Jevtana prescribing information (2023) (opens in a new tab)
  70. Joyce et al. (2023) (opens in a new tab)
  71. Joyce et al. (2024) (opens in a new tab)
  72. Kantoff et al. (2010) (opens in a new tab)
  73. Kaye et al. (2023) (opens in a new tab)
  74. Kaye et al. (2024a) (opens in a new tab)
  75. Kaye et al. (2024b) (opens in a new tab)
  76. Keytruda prescribing information (2026) (opens in a new tab)
  77. Khalaf et al. (2019) (opens in a new tab)
  78. Kirby et al. (2011) (opens in a new tab)
  79. Ku et al. (2017) (opens in a new tab)
  80. Kunst et al. (2025) (opens in a new tab)
  81. Kuppen et al. (2020) (opens in a new tab)
  82. Kwan et al. (2025) (opens in a new tab)
  83. Lloyd et al. (2015) (opens in a new tab)
  84. Lynparza prescribing information (2025) (opens in a new tab)
  85. Mahmud et al. (2026) (opens in a new tab)
  86. Mateo et al. (2026) (opens in a new tab)
  87. Matsubara et al. (2025) (opens in a new tab)
  88. Matsubara et al. (2026) (opens in a new tab)
  89. McDougall et al. (2016) (opens in a new tab)
  90. McKay et al. (2026) (opens in a new tab)
  91. Morgans et al. (2022) (opens in a new tab)
  92. Morgans et al. (2024) (opens in a new tab)
  93. Morris et al. (2015) (opens in a new tab)
  94. Morris et al. (2024a) (opens in a new tab)
  95. Morris et al. (2024b) (opens in a new tab)
  96. Narayan et al. (2024) (opens in a new tab)
  97. National Cancer Institute Prostate Cancer Treatment PDQ (opens in a new tab)
  98. National Cancer Institute SEER Cancer Stat Facts (opens in a new tab)
  99. National Cancer Institute Thesaurus (opens in a new tab)
  100. NCCN (2026) (opens in a new tab)
  101. Nubeqa prescribing information (2026) (opens in a new tab)
  102. ORIC Pharmaceuticals (2020) (opens in a new tab)
  103. ORIC Pharmaceuticals AACR preclinical data release (2026) (opens in a new tab)
  104. ORIC Pharmaceuticals dose exploration completion release (2025) (opens in a new tab)
  105. ORIC Pharmaceuticals early combination data release (2025) (opens in a new tab)
  106. ORIC Pharmaceuticals ESMO preclinical and translational data release (2026) (opens in a new tab)
  107. ORIC Pharmaceuticals expanded access policy (opens in a new tab)
  108. ORIC Pharmaceuticals first quarter results (2026) (opens in a new tab)
  109. ORIC Pharmaceuticals Form 10-K (2026) (opens in a new tab)
  110. ORIC Pharmaceuticals Form 10-Q (2026) (opens in a new tab)
  111. ORIC Pharmaceuticals Himalayas-1 initiation release (2026) (opens in a new tab)
  112. ORIC Pharmaceuticals initial phase 1b data release (2024) (opens in a new tab)
  113. ORIC Pharmaceuticals January presentation (2025) (opens in a new tab)
  114. ORIC Pharmaceuticals November presentation (2025) (opens in a new tab)
  115. ORIC Pharmaceuticals preliminary phase 1b data release (2025) (opens in a new tab)
  116. ORIC Pharmaceuticals presentation (2026) (opens in a new tab)
  117. ORIC Pharmaceuticals RP3D selection release (2026) (opens in a new tab)
  118. ORIC Pharmaceuticals second quarter results (2026) (opens in a new tab)
  119. Oster et al. (2013) (opens in a new tab)
  120. Pankov et al. (2026) (opens in a new tab)
  121. Parekh et al. (2026) (opens in a new tab)
  122. Parker et al. (2013) (opens in a new tab)
  123. Pluvicto prescribing information (2026) (opens in a new tab)
  124. Provenge prescribing information (opens in a new tab)
  125. Rao et al. (2020) (opens in a new tab)
  126. Rathkopf et al. (2018) (opens in a new tab)
  127. Raval et al. (2025) (opens in a new tab)
  128. Raval et al. (2026) (opens in a new tab)
  129. Robinson et al. (2015) (opens in a new tab)
  130. Rubraca prescribing information (2025) (opens in a new tab)
  131. Saad et al. (2002) (opens in a new tab)
  132. Sanyal and Rendon (2026) (opens in a new tab)
  133. Sartor et al. (2021) (opens in a new tab)
  134. Saylor et al. (2020) (opens in a new tab)
  135. Scher et al. (2015) (opens in a new tab)
  136. Scher et al. (2016) (opens in a new tab)
  137. Schweizer et al. (2024) (opens in a new tab)
  138. Schweizer et al. (2025) (opens in a new tab)
  139. Shevrin et al. (2026) (opens in a new tab)
  140. Shore et al. (2021) (opens in a new tab)
  141. Shore et al. (2026a) (opens in a new tab)
  142. Shore et al. (2026b) (opens in a new tab)
  143. Siegel et al. (2026) (opens in a new tab)
  144. Su et al. (2020) (opens in a new tab)
  145. Swami et al. (2023) (opens in a new tab)
  146. Swami et al. (2026) (opens in a new tab)
  147. Talzenna prescribing information (2026) (opens in a new tab)
  148. Tannock et al. (2004) (opens in a new tab)
  149. Taxotere prescribing information (2023) (opens in a new tab)
  150. Tazverik prescribing information (2024) (opens in a new tab)
  151. Teppala et al. (2024a) (opens in a new tab)
  152. Teppala et al. (2024b) (opens in a new tab)
  153. von Amsberg et al. (2026) (opens in a new tab)
  154. Watson et al. (2015) (opens in a new tab)
  155. WHO Drug Information Proposed INN List 133 (2025) (opens in a new tab)
  156. WHO Drug Information Recommended INN List 95 (2026) (opens in a new tab)
  157. Xgeva prescribing information (2026) (opens in a new tab)
  158. Xofigo prescribing information (2019) (opens in a new tab)
  159. Xtandi prescribing information (2026) (opens in a new tab)
  160. Xu et al. (2012) (opens in a new tab)
  161. Yee et al. (2024) (opens in a new tab)
  162. Yu et al. (2025) (opens in a new tab)
  163. Yuen et al. (2025) (opens in a new tab)
  164. Zometa prescribing information (2018) (opens in a new tab)
  165. Zytiga prescribing information (2021) (opens in a new tab)